Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia

DSpace/Manakin Repository

Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia

Citable link to this page

 

 
Title: Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia
Author: Miskin, Dhanashri P.; Chalkias, Spyridon G.; Dang, Xin; Bord, Evelyn; Batson, Stephanie; Koralnik, Igor J.

Note: Order does not necessarily reflect citation order of authors.

Citation: Miskin, Dhanashri P., Spyridon G. Chalkias, Xin Dang, Evelyn Bord, Stephanie Batson, and Igor J. Koralnik. 2016. “Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia.” Neurology® Neuroimmunology & Neuroinflammation 3 (2): e213. doi:10.1212/NXI.0000000000000213. http://dx.doi.org/10.1212/NXI.0000000000000213.
Full Text & Related Files:
Abstract: Objective: To describe the compassionate use of interleukin-7 (IL-7) for treatment of progressive multifocal leukoencephalopathy (PML) in the setting of idiopathic CD8+ greater than CD4+ lymphocytopenia. Methods: A 66-year-old HIV-seronegative man presented with progressive language dysfunction. MRI showed hyperintense lesions in the left hemispheric white matter with mild contrast enhancement. A brain biopsy performed 4 months after symptom onset established the diagnosis of PML. The patient had profound lymphocytopenia with absolute lymphocyte count (ALC) at 168 cells/μL, 87 CD4+ T cells/μL, and 7 CD8+ T cells/μL. There was no evidence of hematologic malignancy or rheumatologic disease. Results: The patient received 3 intramuscular injections of IL-7 at a dose of 10 μg/kg per week with no adverse effects. ALC peaked at 595 cells/μL, CD4+ T cells at 301 cells/μL, and CD8+ T cells at 34 cells/μL 3 weeks after completion of treatment. His lesions on MRI stabilized and neurologic examination mildly improved. JCV-specific T-cell responses measured by intracellular cytokine staining were not altered after treatment with IL-7 but there was a marked increase in regulatory T cells. Conclusion: This case further supports the investigational use of IL-7 in patients who develop PML in the setting of ICL. Classification of evidence: This study provides Class IV evidence that for patients with ICL and PML, IL-7 improves PML-related-outcomes. The study is rated Class IV because it is a case report.
Published Version: doi:10.1212/NXI.0000000000000213
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841501/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320290
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters